Skip to main content
Article thumbnail
Location of Repository

The Oncogenic EWS-FLI1 Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function

By Noëlle Guillon, Franck Tirode, Valentina Boeva, Andrei Zynovyev, Emmanuel Barillot and Olivier Delattre


The fusion between EWS and ETS family members is a key oncogenic event in Ewing tumors and important EWS-FLI1 target genes have been identified. However, until now, the search for EWS-FLI1 targets has been limited to promoter regions and no genome-wide comprehensive analysis of in vivo EWS-FLI1 binding sites has been undertaken. Using a ChIP-Seq approach to investigate EWS-FLI1-bound DNA sequences in two Ewing cell lines, we show that this chimeric transcription factor preferentially binds two types of sequences including consensus ETS motifs and microsatellite sequences. Most bound sites are found outside promoter regions. Microsatellites containing more than 9 GGAA repeats are very significantly enriched in EWS-FLI1 immunoprecipitates. Moreover, in reporter gene experiments, the transcription activation is highly dependent upon the number of repeats that are included in the construct. Importantly, in vivo EWS-FLI1-bound microsatellites are significantly associated with EWS-FLI1-driven gene activation. Put together, these results point out the likely contribution of microsatellite elements to long-distance transcription regulation and to oncogenesis

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1997). A new member of the ETS family fused to EWS in Ewing tumors.
  2. (1996). A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing’s sarcoma.
  3. (1994). A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor,
  4. (2005). A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 59 flanking region of SMYD3 is a risk factor for human cancers.
  5. (1995). A variant Ewing’s sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.
  6. (2001). Biology of EWS/ETS fusions in Ewing’s family tumors.
  7. (1997). Biology of EWS/FLI and related fusion genes in Ewing’s sarcoma and primitive neuroectodermal tumor.
  8. (2006). Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing’s sarcoma cells.
  9. (2006). Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins.
  10. (2008). DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cellcycle progression in Ewing’s tumor cells.
  11. (1995). DNA binding specificities of Spi-1/PU.1 and Spi-B transcription factors and identification of a Spi-1/Spi-B binding site in the c-fes/c-fps promoter.
  12. (2000). DNA binding specificity studies of four ETS proteins support an indirect read-out mechanism of protein-DNA recognition.
  13. (1994). DNAbinding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.
  14. (2005). EWS-ETS oncoproteins: the linchpins of Ewing tumors.
  15. (2005). EWS-FLI1 target genes recovered from Ewing’s sarcoma chromatin.
  16. (2007). EWS/ FLI1 Regulates Tumor Angiogenesis in Ewing’s Sarcoma via Suppression of Thrombospondins.
  17. (2004). EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
  18. (2002). Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays.
  19. (2006). Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing’s sarcoma.
  20. (2008). FindPeaks 3.1: a tool for identifying areas of enrichment from massively parallel short-read sequencing technology.
  21. (1994). Fitting a mixture model by expectation maximization to discover motifs in biopolymers.
  22. (1997). FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements.
  23. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.
  24. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
  25. (2007). Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family.
  26. (2006). Genome-wide computational prediction of transcriptional regulatory modules reveals new insights into human gene expression.
  27. (2008). Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data.
  28. (1996). Harel-Bellan A
  29. (2008). Human VRK1 is an early response gene and its loss causes a block in cell cycle progression.
  30. (2003). Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
  31. Lessnick SL (2006) NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing’s sarcoma.
  32. (2002). Locus control regions.
  33. (2007). Mesenchymal stem cell features of ewing tumors.
  34. (2008). Microsatellites are EWS/FLI response elements: genomic ‘‘junk’’ is EWS/FLI’s treasure.
  35. (2008). Microsatellites as EWS/FLI response elements in Ewing’s sarcoma.
  36. (2007). Nuclear organization of the genome and the potential for gene regulation.
  37. (2004). p53 Stabilization and accumulation induced by human vaccinia-related kinase 1.
  38. (2005). PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing’s Sarcoma tumorigenesis.
  39. (2005). Remote control of gene transcription.
  40. (1999). Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
  41. (2008). RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1.
  42. (2003). Scanning human gene deserts for long-range enhancers.
  43. (2000). Structure of the elk-1-DNA complex reveals how DNA-distal residues affect ETS domain recognition of DNA.
  44. (1998). Structures of SAP-1 bound to DNA targets from the E74 and c-fos promoters: insights into DNA sequence discrimination by Ets proteins.
  45. (1995). The ETS-domain transcription factors Elk-1 and SAP-1 exhibit differential DNA binding specificities.
  46. (1994). The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities.
  47. (2006). The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
  48. (1998). The structure of GABPalpha/beta: an ETS domain- ankyrin repeat heterodimer bound to DNA.
  49. (2005). Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing’s family tumor cells.
  50. (2003). Umezawa A

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.